(Reuters) -Vertex Pharmaceuticals reported on Monday that it beat Wall Street estimates for third-quarter results, driven by strong demand for its cystic fibrosis treatments and early contributions from newer medicines.

The Boston-based company reported total revenue of $3.08 billion for the quarter ended September 30, above analysts’ average estimate of $3.05 billion, according to LSEG data.

Adjusted earnings came in at $4.80 per share, topping expectations of $4.56.

Vertex, a leader in cystic fibrosis drugs, is diversifying into gene therapies, including Casgevy for sickle cell disease and transfusion-dependent beta-thalassemia, and into non-opioid painkillers.

Casgevy generated $16.9 million in quarterly revenue. Since launch, 165 patients have had cells collected for treatment, wit

See Full Page